Table 5 Post-MI treatment in RA and control patients: comparison of three time periods
| Â | Prior to 1999 | 1999 to 2002 inclusive | 2003 onward |
|---|---|---|---|
Acute reperfusion (all patients) | Â | Â | Â |
   RA patients, n (%) | 6/16 (38%) | 4/38 (10%)* | 4/28 (12%) |
   Controls, n (%) | 10/19 (53%) | 17/41 (41%) | 6/30 (20%) |
Acute reperfusion (STEMI patients) | Â | Â | Â |
   RA patients, n (%) | 6/10 (60%) | 4/13 (31%)* | 4/6 (67%) |
   Controls, n (%) | 9/12 (75%) | 14/20 (70%) | 6/7 (86%) |
Thrombolysis | Â | Â | Â |
   RA patients, n (%) | 3/16 (19%) | 3/42 (7%)* | 2/32 (6%) |
   Controls, n (%) | 8/19 (42%) | 12/41 (29%) | 2/30 (7%) |
Percutaneous coronary intervention | Â | Â | Â |
   RA patients, n (%) | 4/16 (25%) | 3/42 (7%)* | 3/32 (9%)* |
   Controls, n (%) | 3/19 (16%) | 15/41 (36%) | 12/30 (40%) |
Aspirin | Â | Â | Â |
   RA patients, n (%) | 14/16 (88%) | 41/42 (98%) | 30/32 (94%) |
   Controls, n (%) | 19/19 (100%) | 41/41 (100%) | 29/30 (97%) |
Beta blockers | Â | Â | Â |
   RA patients, n (%) | 8/16 (50%) | 32/42 (76%) | 24/32 (75%) |
   Controls, n (%) | 15/19 (79%) | 32/41 (78%) | 28/30 (93%) |
ACE inhibitors | Â | Â | Â |
   RA patients, n (%) | 8/16 (50%) | 29/42 (69%) | 24/32 (75%) |
   Controls, n (%) | 14/19 (74%) | 24/41 (58%) | 19/30 (63%) |
Lipid-lowering agents | Â | Â | Â |
   RA patients, n (%) | 0/16 (0)* | 16/42 (38%)* | 20/32 (62%) |
   Controls, n (%) | 7/19 (37%) | 31/41 (76%) | 25/30 (83%) |